|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,501,164
U.S. Patent 8,501,164, titled "Methods for treating neurological disorders," issued on August 6, 2013, to Neurologix, Inc. The patent covers methods of treating certain neurological disorders, specifically attention deficit hyperactivity disorder (ADHD) and Tourette's syndrome, using gene therapy. The core of the patent lies in the administration of a specific adeno-associated virus (AAV) vector carrying the human neuropeptide Y Y1 receptor gene (hY1R) into the subthalamic nucleus (STN) of the brain.
What Does U.S. Patent 8,501,164 Claim?
The patent contains 16 claims. The independent claims, specifically claim 1, define the primary invention. Dependent claims further refine the scope of treatment, target patient populations, and administration details.
Claim 1: Method of Treatment
Claim 1 outlines a method for treating ADHD and Tourette's syndrome. This method involves:
- Delivery of a Gene Therapy Vector: Administering an adeno-associated virus (AAV) vector.
- Vector Cargo: The AAV vector is engineered to carry a nucleic acid sequence encoding the human neuropeptide Y Y1 receptor (hY1R).
- Target Brain Region: The vector is delivered to the subthalamic nucleus (STN) of a subject.
- Therapeutic Goal: The delivery is intended to increase the expression of the hY1R in the STN.
- Subject Population: The method applies to subjects diagnosed with ADHD or Tourette's syndrome.
Dependent Claims: Refinements and Specifics
Dependent claims further define the scope:
- Specific AAV Serotypes: Claims specify the use of particular AAV serotypes, such as AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9. The choice of serotype can influence transduction efficiency and biodistribution.
- Nucleic Acid Sequence Details: Claims may detail the specific form of the nucleic acid, such as a cDNA sequence, or describe regulatory elements included for expression.
- Dosage and Administration: Some claims may specify dosage ranges or administration techniques, although detailed parameters are often left to specific embodiments described in the specification.
- Therapeutic Outcomes: Claims may indirectly reference expected therapeutic outcomes, such as reducing hyperactive behaviors or tics, by describing the intended effect of increasing hY1R expression.
- Subject Characteristics: Claims can specify patient characteristics, such as age or severity of symptoms, for whom the method is intended.
What is the Underlying Scientific Principle?
The patent leverages the role of the neuropeptide Y Y1 receptor (Y1R) in the STN. Y1R is a G protein-coupled receptor that, when activated, can modulate neuronal activity. Research suggests that dysregulation of Y1R signaling in the basal ganglia, including the STN, may contribute to the pathophysiology of movement disorders and conditions characterized by impulsivity and hyperactivity, such as ADHD and Tourette's syndrome.
By delivering a gene encoding hY1R to the STN via an AAV vector, the inventors aim to restore or enhance Y1R signaling in this critical brain region. This is hypothesized to normalize the aberrant neural circuitry underlying these neurological disorders, thereby alleviating symptoms. AAV vectors are favored for gene therapy due to their low immunogenicity, ability to transduce non-dividing cells, and capacity for long-term gene expression [1, 2].
Who is the Patent Holder?
The assignee of U.S. Patent 8,501,164 is Neurologix, Inc. Neurologix was a biotechnology company focused on developing gene therapies for neurological disorders. The company faced significant challenges, including regulatory hurdles and clinical trial outcomes, impacting its development trajectory. In 2015, Neurologix was acquired by GW Pharmaceuticals plc.
What is the Patent Landscape for ADHD and Tourette's Gene Therapies?
The patent landscape for gene therapies targeting ADHD and Tourette's syndrome is evolving. While U.S. Patent 8,501,164 is one of the earlier patents in this specific niche, it is part of a broader landscape encompassing various gene therapy approaches, targets, and delivery systems.
Key elements of the patent landscape include:
- Target Genes and Receptors: Patents may cover other genes or receptor systems implicated in ADHD and Tourette's, such as dopamine receptors, serotonin transporters, or other neurotransmitter systems.
- Delivery Vectors: The landscape includes patents on different viral vectors (e.g., lentivirus, herpes simplex virus) and non-viral delivery methods, as well as modifications to AAV serotypes for improved targeting and efficacy.
- Therapeutic Targets within the Brain: Beyond the STN, other brain regions like the prefrontal cortex, striatum, or globus pallidus might be patented targets for gene therapy interventions in these conditions.
- Methods of Manufacturing: Patents are also filed for the manufacturing processes of gene therapy vectors, ensuring purity, scalability, and safety.
- Combination Therapies: The patent landscape may include claims for combination therapies that involve gene therapy alongside pharmacological treatments.
Comparison to Other Gene Therapy Patents:
- Scope: U.S. Patent 8,501,164 has a relatively focused scope, targeting specific genes (hY1R) and a specific brain region (STN) for particular disorders (ADHD and Tourette's). Many other gene therapy patents may have broader claims covering classes of genes, multiple neurological disorders, or various delivery mechanisms.
- Maturity: As a patent issued in 2013, it represents an earlier stage of development for this specific therapeutic approach. The patent landscape has since expanded with newer technologies and discoveries.
- Clinical Translation: While the patent protects the method, its ultimate commercial value depends on successful clinical trials and regulatory approval. The patent landscape is dynamic, with ongoing research and new patent filings reflecting the latest scientific advancements.
What is the Status of the Patent?
U.S. Patent 8,501,164 is currently in force. Patents typically have a term of 20 years from the filing date, subject to maintenance fees. The filing date for this patent was October 27, 2010, making its expiration date October 27, 2030.
Potential Implications for R&D and Investment
The existence and claims of U.S. Patent 8,501,164 have several implications for companies involved in R&D or investment in the neurological disorder therapeutic space.
- Freedom to Operate (FTO): Companies developing gene therapies for ADHD or Tourette's, particularly those using AAV vectors to target the STN or modulate Y1R signaling, must conduct thorough FTO analyses. This patent may present a barrier if their intended therapy falls within its claimed scope.
- Licensing Opportunities: Companies may seek to license the technology protected by this patent if their R&D aligns with its claims. Given the acquisition of Neurologix by GW Pharmaceuticals, any licensing discussions would now involve GW Pharmaceuticals.
- Strategic Planning: R&D teams must be aware of this patent when designing new therapeutic approaches to avoid infringing existing intellectual property. This may necessitate exploring alternative gene targets, different brain regions, or novel delivery systems.
- Investment Due Diligence: Investors evaluating companies in this sector should assess the IP portfolio of target companies, including any potential conflicts with patents like 8,501,164. The strength and breadth of a patent portfolio are critical indicators of a company's competitive advantage.
- Competitive Analysis: Understanding this patent helps map out the competitive landscape. It highlights specific technological approaches that have been previously protected, guiding future innovation and differentiation strategies.
Key Takeaways
U.S. Patent 8,501,164 protects a gene therapy method for treating ADHD and Tourette's syndrome by delivering an AAV vector encoding the hY1R gene to the subthalamic nucleus. The patent, issued in 2013 to Neurologix, Inc. (now part of GW Pharmaceuticals), is valid until October 27, 2030. Companies operating in this therapeutic area must consider this patent for freedom to operate, potential licensing, and strategic R&D planning. The patent represents a specific, early-stage gene therapy approach within a broader and evolving field.
Frequently Asked Questions
-
What is the primary therapeutic target of U.S. Patent 8,501,164?
The patent targets the enhancement of human neuropeptide Y Y1 receptor (hY1R) expression in the subthalamic nucleus (STN) of the brain.
-
Which neurological disorders does this patent specifically cover?
The patent covers methods for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
-
What type of gene therapy vector is described in the patent?
The patent describes the use of an adeno-associated virus (AAV) vector engineered to carry the nucleic acid sequence encoding the hY1R.
-
Who is the current rights holder of U.S. Patent 8,501,164?
The patent was originally assigned to Neurologix, Inc., which was acquired by GW Pharmaceuticals plc. Therefore, GW Pharmaceuticals is the current rights holder.
-
When does U.S. Patent 8,501,164 expire?
The patent has an expiration date of October 27, 2030.
Citations
[1] Asano, Y., & Oya, Y. (2019). Adeno-associated virus (AAV) vector. Advanced Drug Delivery Reviews, 147, 93-109.
[2] Chadderton, P. B., & Flannery, J. G. (2021). Gene therapy vectors: Development and applications. Drug Discovery Today, 26(7), 1739-1747.
More… ↓
⤷ Start Trial
|
